业务新闻
24 Mar 2021
GEA is committed to “Engineering for a better world,” designing and building modular plants and fully integrated systems that meet the extremely high demands of today’s biotechnology and pharmaceutical industries. (Courtesy: Damian Poffet)
Despite the incredible achievements that have been made in terms of developing and delivering a number of approved and administered Covid-19 vaccines in recent times, governments, politicians and the general public alike are still questioning why it takes 3-5 years to bring a commercial-scale biopharmaceutical manufacturing plant to full operational functionality.
Furthermore, they want to know what can be done about it. GEA Group’s Heinrich Meintrup, Head of Pharma & Healthcare, believes that the key to significantly shortening this timeframe is modularization, digitalization and collaboration. In his presentation, “How Can We Fast-Track Vaccine Plant Production and Ensure Safety of Outcome?” he will explain how, based on a foundation of trust and existing know-how, working with a partnership approach can reduce the complexity, cost and risk of successful drug production.
By subscribing to a philosophy of standardization and modularization, a digitally enhanced project delivery process and keeping the number of interfaces to a minimum, significant gains can be made.
“We have to make the best use of existing intelligent solutions,” advises Meintrup, “adhere to current standards and regulations, and focus on mutually agreed targets and incentives. Disruptions and delays can cost millions of dollars; but, by taking a smarter and leaner approach, GEA believes that the design, construction and qualification of pharmaceutical manufacturing plant and facilities can be accelerated, simplified and delivered with predictable outcomes in a shorter timeframe.”
Dr. Michael Golek
Media Relations
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468
Düsseldorf
Germany
+49 211 9136-0
GEA 是食品加工行业及众多工业领域的领先供应商之一,2019 年的销售总额约达 49 亿欧元。